The study of irritant and allergy testing of Prasakhaminchan extract cream in healthy volunteers (Clinical Trial Phase I)

Curcuma longa Linn. Harrisonia perforata (Blanco) Merr. Capparis micracantha DC. Clerodendrum petasites S.Moore. Ficus racemosa Linn. Tiliacora triandra Diels.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190112001

Enrollment

Unknown

Registered

2019-01-12

Start date

2017-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prasakhaminchan formula has high potential to be a topical medication for inflammatory skin diseases or Dermatitis. Dermatitis is a common skin disease group and patients in this group was approximate Prasakhaminchan&#44

Interventions

The medicinal formula were extracted with 95% ethanol and vacuum dried. The closed skin patch test was performed in 30 healthy volunteers for 48 hours. The test samples included Ha&#45

Rak extract&#44

turmeric extract&#44

Prasakhaminchan extract in white petrolatum and cream base at the concentrations of 0.25%&#44

0.5%&#44

1%&#44

3%&#44

5% and 10% w/w.

Active Comparator Drug

Prasakhaminchan

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. healthy volunteers 2. Male and Female between age 18 -60 years 3. Voluntarily participating after listen to explanation of research process until it is understood. And not participants in other trial .

Exclusion criteria

Exclusion criteria: 1. Rashes, dermatitis, swelling or allergic skin lesions on back. 2. There are symptoms and history of liver disease, kidney disease or other serious illnesses. 3. Volunteers eat or topical anti-allergy or drug Corticosteroids or other drugs that are effective immunosuppression during the test and should be discontinued at least two weeks before the test 4. Pregnant or who wanted to have a child in conducting research. Including lactating women 5. Those who have a history drug allergy in Ha-Rak, turmeric, and plaster or micropore/microfilm.

Design outcomes

Primary

Measure	Time frame
irritant and allergy at 24 months after end of the intervention Grading criteria of skin reactions by CTFA Guideline	—

Secondary

Measure	Time frame
number of volunteers at 24 months after end of the intervention History and physical examination	—

Countries

Thailand

Contacts

Public ContactNuengruetai Srichaipor

Center of Excellence on Applied Thai Traditional Medicine Research(CEATMR)

bo_ns@hotmail.com+668 52172169

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026